Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Change in Cash (2016 - 2025)

Historic Change in Cash for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 17 years, with Q2 2025 value amounting to $2.8 million.

  • Lifecore Biomedical, Inc. \De\'s Change in Cash fell 4715.16% to $2.8 million in Q2 2025 from the same period last year, while for May 2025 it was -$197000.0, marking a year-over-year increase of 9814.66%. This contributed to the annual value of -$197000.0 for FY2025, which is 9814.66% up from last year.
  • As of Q2 2025, Lifecore Biomedical, Inc. \De\'s Change in Cash stood at $2.8 million, which was down 4715.16% from -$4.0 million recorded in Q1 2025.
  • In the past 5 years, Lifecore Biomedical, Inc. \De\'s Change in Cash registered a high of $16.1 million during Q2 2023, and its lowest value of -$10.4 million during Q3 2023.
  • In the last 5 years, Lifecore Biomedical, Inc. \De\'s Change in Cash had a median value of -$179500.0 in 2022 and averaged $320777.8.
  • As far as peak fluctuations go, Lifecore Biomedical, Inc. \De\'s Change in Cash surged by 774976.3% in 2023, and later plummeted by 262837.84% in 2025.
  • Over the past 5 years, Lifecore Biomedical, Inc. \De\'s Change in Cash (Quarter) stood at -$356000.0 in 2021, then skyrocketed by 832.58% to $2.6 million in 2022, then crashed by 307.86% to -$5.4 million in 2023, then skyrocketed by 172.59% to $3.9 million in 2024, then fell by 27.62% to $2.8 million in 2025.
  • Its last three reported values are $2.8 million in Q2 2025, -$4.0 million for Q1 2025, and $3.9 million during Q4 2024.